ANI Pharmaceuticals (ANIP) announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel for the treatment of acute gout flares. Cortrophin Gel is indicated for short-term administration as an adjunctive therapy during an acute episode or exacerbation in acute gouty arthritis. Cortrophin Gel is contraindicated for intravenous administration.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Releases May 2025 Financial Presentation
- ANI Pharmaceuticals: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- ANI Pharmaceuticals price target raised to $86 from $84 at Raymond James
- ANI Pharmaceuticals Reports Record Q1 2025 Results
- ANI Pharmaceuticals Reports Record Growth in Earnings Call